Expanded Liquid Testing With Genomic and Epigenomic Insights
Guardant360 Liquid is the first and only liquid biopsy to deliver genomic and epigenomic insights for a more complete view of cancer.1 By analyzing cell-free DNA, Guardant360 Liquid helps healthcare providers detect actionable genomic and epigenomic alterations to guide personalized treatment and monitor tumor evolution.
A Fast CGP Panel with Guideline-Recommended Actionable Biomarkers
Our Guardant360 CDx test is our FDA-approved liquid biopsy that provides results in 7 days upon sample receipt in the laboratory to inform treatment decisions.2
Unlock Maximum Insights From Minimal Tissue With Advanced Multiomics
Guardant360 Tissue is a multiomic test for patients with advanced solid tumors, providing comprehensive genomic, transcriptomic, and epigenomic insights3 using minimal tissue—requiring 92% less surface area4 and 40% fewer slides than the industry standard.5
Minimal Residual Disease Detection and Therapy Response Monitoring
Guardant Reveal is a simple blood test that utilizes circulating tumor DNA (ctDNA) to detect cancer at the molecular level, offering a more precise, ctDNA-guided approach to cancer monitoring. Guardant Reveal is available for molecular residual disease (MRD) detection and recurrence monitoring in early-stage colorectal, breast, and lung cancers and for therapy response monitoring in advanced cancer.
